MetLife Investment Management’s Galectin Therapeutics GALT Stock Holding History

MetLife Investment Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$134K	Buy	+28,875	New	+$74.8K	﹤0.01%	2634

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MetLife Investment Management's GALT Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 28,875 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #2634 among its holdings.

98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

MetLife Investment Management held 28,875 shares of Galectin Therapeutics worth $134K as of Q2 2026.
Galectin Therapeutics was a new MetLife Investment Management position in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2634 holding.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.